Current endocrine and targeted treatment of metastatic ER+ breast cancer
Current endocrine and targeted treatment of metastatic ER+ breast cancer. Antiestrogen therapy including selective estrogen receptor modulators (tamoxifen), aromatase inhibitors (anastrazole, letrozole, exemestane), and selective estrogen receptor degraders (fulvestrant) continues to be the treatment backbone of hormone receptor-positive breast cancer since tamoxifen FDA approval in 1977. Improvement in the understanding of the molecular biology of estrogen-positive breast cancer led to the development of effective targeted therapies such as CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) and inhibitors of PI3K/Akt/mTOR signaling pathway (alpelisib, capivasertib), as well as improvement in the delivery and potency of traditional endocrine therapy including oral selective estrogen receptor degraders (elacestrant). * Anticipated regulatory approval during the fourth quarter of 2023. Abbreviations: AKT, AKT Serine/Threonine Kinase 1; CDK, cyclin-dependent kinase; ER, estrogen receptor; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinases; SERD, selective estrogen receptor degraders; SERM, selective estrogen receptor modulator
Publication
Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches (2023) Farah Raheem, et al. Int J Mol Sci. 2023 Nov;24(22). Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | CDK4/6 | CDK4 | ncbigene_symbol | CDK4 | 1019 |
| Homo sapiens | Primates | CDK4/6 | CDK6 | ncbigene_symbol | CDK6 | 1021 |
| Homo sapiens | Primates | AKT | AKT | ncbigene_synonym | AKT1 | 207 |
| Homo sapiens | Primates | AKT | AKT | famplex_relations | AKT2 | 208 |
| Homo sapiens | Primates | AKT | AKT | famplex_relations | AKT3 | 10000 |
| Homo sapiens | Primates | mTOR | MTOR | ncbigene_symbol | MTOR | 2475 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Anastrozole | anastrozole | 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile) | chebi:2704 | |
| Inhibitor | inhibitor | inhibitor | chebi:35222 | |
| Letrozole | letrozole | 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile | chebi:6413 | |
| inhibitors | inhibitors | inhibitor | chebi:35222 | |
| Exemestane | exemestane | 6-methylideneandrosta-1,4-diene-3,17-dione | chebi:4953 | |
| Fulvestrant | fulvestrant | 7alpha-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17beta-diol | chebi:31638 | |
| Palbociclib | palbociclib | 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one | chebi:85993 | |
| Elacestrant | elacestrant | (6R)-6-[2-(ethyl{4-[2-(ethylamino)ethyl]benzyl}amino)-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol | chebi:229213 | |
| Tamoxifen | tamoxifen | 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine | chebi:41774 | |
| inhibitor | inhibitor | inhibitor | chebi:35222 | |
| inhibitor | inhibitor | inhibitor | chebi:35222 | |
| Everolimus | everolimus | (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone | chebi:68478 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|